Bourla had said that the company could submit for approval in late October based on data showing that enough people in a trial group that had received a placebo version of the vaccine had gotten COVID-19 compared to the group that received the actual shot.
The Food and Drug Administration slightly extended the timeline for any company to file for an emergency use authorization earlier this month when it communicated to companies that it would require two months of safety data to be collected on at least half of the patients in a company's clinical trial.
Several drugmakers including Pfizer, AstraZeneca, Johnson & Johnson and Novavax Inc have said they expect to produce at least 1 billion doses of their vaccines next year if they get regulatory authorization.
Vector, a lab in the outskirts of Novosibirsk that worked to weaponise smallpox during the Soviet period, developed its vaccine using peptide antigens, or synthetic fragments of the virus, to provoke an immune response to Covid-19.
The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG).
"So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the United States soon after the safety milestone is achieved in the third week of November", Pfizer Chief Executive Albert Bourla said, noting that he published the letter to provide greater clarity on the timeline for the vaccine.
"We are proud that Indian manufacturers will make most of the world's supply of vaccine, and as healthcare service providers we will ensure the safest and most comprehensive delivery", said Kanineni.
Spotify gets iOS 14 widget, available in two sizes
The iPhone 12 mini , iPhone 12, iPhone 12 Pro, and iPhone 12 Pro Max all debuted during Tuesday's online Apple event. In addition to the iPhone 12 , Apple made another important announcement that did not pass so much notice.
"Novosibirsk's Vektor [State Virology and Biotechnology Center] has registered the second Russian coronavirus vaccine today", Putin said via televised video conference.
- The independent data safety monitoring board, a panel of experts monitoring the study, will conduct interim analyses of the effectiveness of the vaccine.
Bourla estimated that Pfizer's 44,000-person study would reach that milestone in the third week of November.
Could these be the first approved coronavirus vaccines? During a digital event in September, he also said the company expected initial results in late October and would seek FDA authorization as soon as possible.
This comes at a time when COVID-19 cases in the USA are climbing slightly, but the coronavirus deaths are relatively level this month.
While it's banning misinformation about COVID-19 vaccines, YouTube said it will still allow videos that provide a broader discussion about issues and concerns about the safety of such vaccines.
U.S. health officials have sought to assuage those concerns.